Serum concentrations and side effects in psychiatric patients during risperidone therapy

Therapeutic Drug Monitoring

Volumn 20, Issue 4, 1998, Pages 380-384

  Olesen, Ole V ^a   Licht, Rasmus W ^a   Thomsen, Erik ^a   Bruun, Troels ^a   Viftrup, Jens Emil ^a   Linnet, Kristian ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Risperidone; Serum concentration; Side effects

Indexed keywords

FLUOXETINE; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; HUMAN; MALE; MENTAL DISEASE; METABOLIC INHIBITION; PRIORITY JOURNAL;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; FEMALE; GENOTYPE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PSYCHOTROPIC DRUGS; PYRIMIDINES; RISPERIDONE;

EID: 0031828859     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199808000-00004     Document Type: Article

References (16)

1. Chouinard G, Arnott W. Clinical review of risperidone. Can J Psychiatry 1993;38(suppl 3):89-95.
2. He H, Richardson JS. A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. Int Clin Psychopharmacology 1995;10:19-30.
3. Schotte A, Janssen PFM, Megens AAHP, Leysen JE. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res 1993;631:191-202.
4. Van Beijsterveldt LE, Geerts RJ, Leysen JE, et al. Regional brain distribution of risperidone and its active metabolite 9-hydroxyrisperidone in the rat. Psychopharmacology (Berl) 1994;114:53-62.
5. Heykants J, Huang M-L, Mannens G, et al. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 1994;55: 13-7.
6. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
7. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
8. Huang M, Van Peer A, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993;54:257-68.
9. Bech P, Kastrup M, Rafaelsen OJ. Mini-compendium of rating scales for states of anxiety, depression, mania, schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr Scand 1986;73 (suppl):32-6.
10. Olesen OV, Linnet K. Simplified high-performance liquid Chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs. J Chromatogr 1997;698:209-16.
11. Heim MH, Meyer VA. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 1990;336: 529-32.
12. Ketter TA, Flockhart DA, Post RM, et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 1995;15:387-98.
13. Sumiyoshi T, Kido H, Sakamoto H, et al. In vivo dopamine-D2 and serotonin-5-HT2 receptor binding study of risperidone and haloperidol. Pharmacol Biochem Behav 1994;47:553-7.
14. Snoeck E, Van Peer A, Sack M, et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology 1995;122:223-229.
15. Mannens G, Huang M, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J. Absorption, metabolism and excretion of risperidone in humans. Drug Metab Dispos 1993;21:1134-41.
16. Ereshefsky L, Lacombe S. Pharmacological profile of risperidone. Can J Psychiatry 1993;38(suppl):80-8.